Equity
Unrealized Losses on Investments (Before Tax)
Neurocrine Biosciences Unrealized Losses on Investments (Before Tax) increased by 1100.0% to $7.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1100.0%, from $600.00K to $7.20M. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ4 2024
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests rising interest rates or credit deterioration in the underlying assets, which may pressure capital levels.
Detailed definition
These represent the decline in market value of investment securities below their amortized cost, which have not yet been...
Peer comparison
A key focus area for investors during periods of interest rate volatility across the banking sector.
Metric ID:
unrealized_losses_on_investmentsHistorical Data
6 periods
| Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $1.70M | $600.00K | $500.00K | $500.00K | $600.00K | $7.20M |
| QoQ Change | — | -64.7% | -16.7% | +0.0% | +20.0% | >999% |
| YoY Change | — | — | — | — | -64.7% | >999% |
Range$500.00K – $7.20M
CAGR+217.3%
Avg YoY Growth+517.6%
Median YoY Growth+517.6%
Current Streak3 quarters growth
Unrealized Losses on Investments (Before Tax) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's unrealized losses on investments (before tax)?
- Neurocrine Biosciences (NBIX) reported unrealized losses on investments (before tax) of $7.20M in Q1 2026.
- How has Neurocrine Biosciences's unrealized losses on investments (before tax) changed year-over-year?
- Neurocrine Biosciences's unrealized losses on investments (before tax) increased by 1100.0% year-over-year, from $600.00K to $7.20M.
- What does unrealized losses on investments (before tax) mean?
- Paper losses on investments that the bank still holds.